APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatology Drug

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. These medications can be prescription or over-the-counter and can be administered in various forms such as oral, topical (creams, gels, ointments), and injectable.

Common types of dermatology drugs include:

a. Antibiotics: Used to treat bacterial infections, such as acne and cellulitis.

b. Antifungal agents: Used to treat fungal infections, such as ringworm and candidiasis.

c. Antiviral medications: Used to treat viral infections, such as shingles and warts.

d. Steroids: Used to reduce inflammation and allergic reactions, commonly used for eczema and psoriasis.

e. Immunomodulators: Used to modulate the immune system, such as tacrolimus and pimecrolimus.

f. Vitamin D analogs: Used to treat psoriasis, such as calcipotriene.

g. Keratolytics: Used to treat acne by promoting exfoliation, such as benzoyl peroxide and retinoids.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Dermatology Drug, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable dermatology drug performance?

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Market Outlook & Growth Opportunities

Global Dermatology Drug Market Outlook and Growth Opportunities 2026

21 December 2025218 pages

Choose your research edition.

Industry ResearchDermatology Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatology Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Dermatology Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatology Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatology Drug Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. These medications can be prescription or over-the-counter and can be administered in various forms such as oral, topical (creams, gels, ointments), and injectable.

Common types of dermatology drugs include:

a. Antibiotics: Used to treat bacterial infections, such as acne and cellulitis.

Read the full market overview

b. Antifungal agents: Used to treat fungal infections, such as ringworm and candidiasis.

c. Antiviral medications: Used to treat viral infections, such as shingles and warts.

d. Steroids: Used to reduce inflammation and allergic reactions, commonly used for eczema and psoriasis.

e. Immunomodulators: Used to modulate the immune system, such as tacrolimus and pimecrolimus.

f. Vitamin D analogs: Used to treat psoriasis, such as calcipotriene.

g. Keratolytics: Used to treat acne by promoting exfoliation, such as benzoyl peroxide and retinoids.

The global Dermatology Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dermatology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Dermatology Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dermatology Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dermatology Drug market include AbbVie, Johnson & Johnson, Bayer, Galderma, Bristol-Myers Squibb, Novartis, Pfizer, Merz Pharma and Valeant, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Dermatology Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatology Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatology Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Dermatology Drug market.

Dermatology Drug Segment by Company

AbbVie

Johnson & Johnson

Bayer

Galderma

Bristol-Myers Squibb

Novartis

Pfizer

Merz Pharma

Valeant

Leo Pharma A/S

GlaxoSmithKline (GSK)

Allergan

Almirall S.A.

Amgen

Astellas

Concert Pharmaceuticals

Eli Lilly and Company

Lupin

Mayne Pharma

Merck KGaA

AstraZeneca plc

Roivant Sciences (Dermavant Sciences)

Dermatology Drug Segment by Type

External Use

Oral

Injection

Dermatology Drug Segment by Application

Psoriasis

Skin Infections

Acne

Dermatitis

Others

Dermatology Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dermatology Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Dermatology Drug key companies, revenue, market share, and recent developments.

3. To split the Dermatology Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Dermatology Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dermatology Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Dermatology Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatology Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatology Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatology Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatology Drug industry.

Chapter 3: Detailed analysis of Dermatology Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Dermatology Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Dermatology Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dermatology Drug Industry Trends Table 2. Dermatology Drug Industry Drivers Table 3. Dermatology Drug Industry Opportunities and Challenges Table 4. Dermatology Drug Industry Restraints Table 5. Global Dermatology Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dermatology Drug Revenue Share by Company (2021-2026) Table 7. Global Dermatology Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Dermatology Drug Key Company Manufacturing Base & Headquarters Table 9. Global Dermatology Drug Company, Product Type & Application Table 10. Global Dermatology Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Dermatology Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of External Use Table 15. Significant Companies of Oral Table 16. Significant Companies of Injection Table 17. Global Dermatology Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Dermatology Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Dermatology Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Dermatology Drug Sales Value Share by Type (2021-2026) Table 21. Global Dermatology Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Psoriasis Table 23. Significant Companies of Skin Infections Table 24. Significant Companies of Acne Table 25. Significant Companies of Dermatitis Table 26. Significant Companies of Others Table 27. Global Dermatology Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Dermatology Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Dermatology Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Dermatology Drug Sales Value Share by Application (2021-2026) Table 31. Global Dermatology Drug Sales Value Share by Application (2027-2032) Table 32. Global Dermatology Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Dermatology Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Dermatology Drug Sales Value Share by Region (2021-2026) Table 35. Global Dermatology Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Dermatology Drug Sales Value Share by Region (2027-2032) Table 37. Global Dermatology Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Dermatology Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Dermatology Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Dermatology Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Dermatology Drug Sales Value Market Share by Country (2027-2032) Table 42. AbbVie Company Information Table 43. AbbVie Business Overview Table 44. AbbVie Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. AbbVie Dermatology Drug Product Portfolio Table 46. AbbVie Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Johnson & Johnson Dermatology Drug Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Bayer Company Information Table 53. Bayer Business Overview Table 54. Bayer Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Bayer Dermatology Drug Product Portfolio Table 56. Bayer Recent Development Table 57. Galderma Company Information Table 58. Galderma Business Overview Table 59. Galderma Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Galderma Dermatology Drug Product Portfolio Table 61. Galderma Recent Development Table 62. Bristol-Myers Squibb Company Information Table 63. Bristol-Myers Squibb Business Overview Table 64. Bristol-Myers Squibb Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Bristol-Myers Squibb Dermatology Drug Product Portfolio Table 66. Bristol-Myers Squibb Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis Dermatology Drug Product Portfolio Table 71. Novartis Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Pfizer Dermatology Drug Product Portfolio Table 76. Pfizer Recent Development Table 77. Merz Pharma Company Information Table 78. Merz Pharma Business Overview Table 79. Merz Pharma Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Merz Pharma Dermatology Drug Product Portfolio Table 81. Merz Pharma Recent Development Table 82. Valeant Company Information Table 83. Valeant Business Overview Table 84. Valeant Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Valeant Dermatology Drug Product Portfolio Table 86. Valeant Recent Development Table 87. Leo Pharma A/S Company Information Table 88. Leo Pharma A/S Business Overview Table 89. Leo Pharma A/S Dermatology Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Leo Pharma A/S Dermatology Drug Product Portfolio Table 91. Leo Pharma A/S Recent Development Table 92. GlaxoSmithKline (GSK) Company Information Table 93. GlaxoSmithKline (GSK) Business Overview Table 94. GlaxoSmithKline (GSK) Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. GlaxoSmithKline (GSK) Dermatology Drug Product Portfolio Table 96. GlaxoSmithKline (GSK) Recent Development Table 97. Allergan Company Information Table 98. Allergan Business Overview Table 99. Allergan Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Allergan Dermatology Drug Product Portfolio Table 101. Allergan Recent Development Table 102. Almirall S.A. Company Information Table 103. Almirall S.A. Business Overview Table 104. Almirall S.A. Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Almirall S.A. Dermatology Drug Product Portfolio Table 106. Almirall S.A. Recent Development Table 107. Amgen Company Information Table 108. Amgen Business Overview Table 109. Amgen Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Amgen Dermatology Drug Product Portfolio Table 111. Amgen Recent Development Table 112. Astellas Company Information Table 113. Astellas Business Overview Table 114. Astellas Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Astellas Dermatology Drug Product Portfolio Table 116. Astellas Recent Development Table 117. Concert Pharmaceuticals Company Information Table 118. Concert Pharmaceuticals Business Overview Table 119. Concert Pharmaceuticals Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Concert Pharmaceuticals Dermatology Drug Product Portfolio Table 121. Concert Pharmaceuticals Recent Development Table 122. Eli Lilly and Company Company Information Table 123. Eli Lilly and Company Business Overview Table 124. Eli Lilly and Company Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Eli Lilly and Company Dermatology Drug Product Portfolio Table 126. Eli Lilly and Company Recent Development Table 127. Lupin Company Information Table 128. Lupin Business Overview Table 129. Lupin Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Lupin Dermatology Drug Product Portfolio Table 131. Lupin Recent Development Table 132. Mayne Pharma Company Information Table 133. Mayne Pharma Business Overview Table 134. Mayne Pharma Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Mayne Pharma Dermatology Drug Product Portfolio Table 136. Mayne Pharma Recent Development Table 137. Merck KGaA Company Information Table 138. Merck KGaA Business Overview Table 139. Merck KGaA Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Merck KGaA Dermatology Drug Product Portfolio Table 141. Merck KGaA Recent Development Table 142. AstraZeneca plc Company Information Table 143. AstraZeneca plc Business Overview Table 144. AstraZeneca plc Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. AstraZeneca plc Dermatology Drug Product Portfolio Table 146. AstraZeneca plc Recent Development Table 147. Roivant Sciences (Dermavant Sciences) Company Information Table 148. Roivant Sciences (Dermavant Sciences) Business Overview Table 149. Roivant Sciences (Dermavant Sciences) Dermatology Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Roivant Sciences (Dermavant Sciences) Dermatology Drug Product Portfolio Table 151. Roivant Sciences (Dermavant Sciences) Recent Development Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Dermatology Drug Product Image Figure 2. Global Dermatology Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatology Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatology Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. External Use Image Figure 8. Oral Image Figure 9. Injection Image Figure 10. Global Dermatology Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Dermatology Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Dermatology Drug Sales Value Share by Type (2021-2032) Figure 13. Psoriasis Image Figure 14. Skin Infections Image Figure 15. Acne Image Figure 16. Dermatitis Image Figure 17. Others Image Figure 18. Global Dermatology Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Dermatology Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Dermatology Drug Sales Value Share by Application (2021-2032) Figure 21. Global Dermatology Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Dermatology Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Dermatology Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Dermatology Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Dermatology Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Dermatology Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Dermatology Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Dermatology Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Dermatology Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Dermatology Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Dermatology Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Dermatology Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Dermatology Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Dermatology Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Dermatology Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • External Use
  • Oral
  • Injection
Applications
  • Psoriasis
  • Skin Infections
  • Acne
  • Dermatitis
  • Others
Companies covered
  • AbbVie
  • Johnson & Johnson
  • Bayer
  • Galderma
  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • Merz Pharma
  • Valeant
  • Leo Pharma A/S
  • GlaxoSmithKline (GSK)
  • Allergan
  • Almirall S.A.
  • Amgen
  • Astellas
  • Concert Pharmaceuticals
  • Eli Lilly and Company
  • Lupin
  • Mayne Pharma
  • Merck KGaA
  • AstraZeneca plc
  • Roivant Sciences (Dermavant Sciences)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dermatology Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dermatology Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Dermatology Drug Market Dynamics
  1. 2.1 Dermatology Drug Industry Trends
  2. 2.2 Dermatology Drug Industry Drivers
  3. 2.3 Dermatology Drug Industry Opportunities and Challenges
  4. 2.4 Dermatology Drug Industry Restraints
3 Dermatology Drug Market by Company
  1. 3.1 Global Dermatology Drug Company Revenue Ranking in 2025
  2. 3.2 Global Dermatology Drug Revenue by Company (2021-2026)
  3. 3.3 Global Dermatology Drug Company Ranking (2024-2026)
  4. 3.4 Global Dermatology Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Dermatology Drug Company Product Type and Application
  6. 3.6 Global Dermatology Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Dermatology Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Dermatology Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Dermatology Drug Market by Type
  1. 4.1 Dermatology Drug Type Introduction
  2. 4.1.1 External Use
  3. 4.1.2 Oral
  4. 4.1.3 Injection
  5. 4.2 Global Dermatology Drug Sales Value by Type
  6. 4.2.1 Global Dermatology Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Dermatology Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Dermatology Drug Sales Value Share by Type (2021-2032)
5 Dermatology Drug Market by Application
  1. 5.1 Dermatology Drug Application Introduction
  2. 5.1.1 Psoriasis
  3. 5.1.2 Skin Infections
  4. 5.1.3 Acne
  5. 5.1.4 Dermatitis
  6. 5.1.5 Others
  7. 5.2 Global Dermatology Drug Sales Value by Application
  8. 5.2.1 Global Dermatology Drug Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Dermatology Drug Sales Value by Application (2021-2032)
  10. 5.2.3 Global Dermatology Drug Sales Value Share by Application (2021-2032)
6 Dermatology Drug Regional Value Analysis
  1. 6.1 Global Dermatology Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatology Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Dermatology Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Dermatology Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dermatology Drug Sales Value (2021-2032)
  7. 6.3.2 North America Dermatology Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Dermatology Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Dermatology Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Dermatology Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Dermatology Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Dermatology Drug Sales Value (2021-2032)
  16. 6.6.2 South America Dermatology Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Dermatology Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Dermatology Drug Sales Value Share by Country, 2025 VS 2032
7 Dermatology Drug Country-level Value Analysis
  1. 7.1 Global Dermatology Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dermatology Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Dermatology Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Dermatology Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Dermatology Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Dermatology Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Dermatology Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Dermatology Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Dermatology Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Dermatology Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Dermatology Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Dermatology Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Dermatology Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Dermatology Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Dermatology Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Dermatology Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Dermatology Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Dermatology Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Dermatology Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Dermatology Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Dermatology Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Dermatology Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Dermatology Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Dermatology Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Dermatology Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Dermatology Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Dermatology Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Dermatology Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Dermatology Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Dermatology Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Dermatology Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Dermatology Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Dermatology Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Dermatology Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Dermatology Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Dermatology Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Dermatology Drug Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Dermatology Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Dermatology Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Dermatology Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Dermatology Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Galderma
  20. 8.4.1 Galderma Company Information
  21. 8.4.2 Galderma Business Overview
  22. 8.4.3 Galderma Dermatology Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Galderma Dermatology Drug Product Portfolio
  24. 8.4.5 Galderma Recent Developments
  25. 8.5 Bristol-Myers Squibb
  26. 8.5.1 Bristol-Myers Squibb Company Information
  27. 8.5.2 Bristol-Myers Squibb Business Overview
  28. 8.5.3 Bristol-Myers Squibb Dermatology Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Dermatology Drug Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Dermatology Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Dermatology Drug Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Dermatology Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Dermatology Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Merz Pharma
  44. 8.8.1 Merz Pharma Company Information
  45. 8.8.2 Merz Pharma Business Overview
  46. 8.8.3 Merz Pharma Dermatology Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merz Pharma Dermatology Drug Product Portfolio
  48. 8.8.5 Merz Pharma Recent Developments
  49. 8.9 Valeant
  50. 8.9.1 Valeant Company Information
  51. 8.9.2 Valeant Business Overview
  52. 8.9.3 Valeant Dermatology Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Valeant Dermatology Drug Product Portfolio
  54. 8.9.5 Valeant Recent Developments
  55. 8.10 Leo Pharma A/S
  56. 8.10.1 Leo Pharma A/S Company Information
  57. 8.10.2 Leo Pharma A/S Business Overview
  58. 8.10.3 Leo Pharma A/S Dermatology Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Leo Pharma A/S Dermatology Drug Product Portfolio
  60. 8.10.5 Leo Pharma A/S Recent Developments
  61. 8.11 GlaxoSmithKline (GSK)
  62. 8.11.1 GlaxoSmithKline (GSK) Company Information
  63. 8.11.2 GlaxoSmithKline (GSK) Business Overview
  64. 8.11.3 GlaxoSmithKline (GSK) Dermatology Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline (GSK) Dermatology Drug Product Portfolio
  66. 8.11.5 GlaxoSmithKline (GSK) Recent Developments
  67. 8.12 Allergan
  68. 8.12.1 Allergan Company Information
  69. 8.12.2 Allergan Business Overview
  70. 8.12.3 Allergan Dermatology Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Allergan Dermatology Drug Product Portfolio
  72. 8.12.5 Allergan Recent Developments
  73. 8.13 Almirall S.A.
  74. 8.13.1 Almirall S.A. Company Information
  75. 8.13.2 Almirall S.A. Business Overview
  76. 8.13.3 Almirall S.A. Dermatology Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Almirall S.A. Dermatology Drug Product Portfolio
  78. 8.13.5 Almirall S.A. Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Dermatology Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Dermatology Drug Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 Astellas
  86. 8.15.1 Astellas Company Information
  87. 8.15.2 Astellas Business Overview
  88. 8.15.3 Astellas Dermatology Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Dermatology Drug Product Portfolio
  90. 8.15.5 Astellas Recent Developments
  91. 8.16 Concert Pharmaceuticals
  92. 8.16.1 Concert Pharmaceuticals Company Information
  93. 8.16.2 Concert Pharmaceuticals Business Overview
  94. 8.16.3 Concert Pharmaceuticals Dermatology Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Concert Pharmaceuticals Dermatology Drug Product Portfolio
  96. 8.16.5 Concert Pharmaceuticals Recent Developments
  97. 8.17 Eli Lilly and Company
  98. 8.17.1 Eli Lilly and Company Company Information
  99. 8.17.2 Eli Lilly and Company Business Overview
  100. 8.17.3 Eli Lilly and Company Dermatology Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Eli Lilly and Company Dermatology Drug Product Portfolio
  102. 8.17.5 Eli Lilly and Company Recent Developments
  103. 8.18 Lupin
  104. 8.18.1 Lupin Company Information
  105. 8.18.2 Lupin Business Overview
  106. 8.18.3 Lupin Dermatology Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Lupin Dermatology Drug Product Portfolio
  108. 8.18.5 Lupin Recent Developments
  109. 8.19 Mayne Pharma
  110. 8.19.1 Mayne Pharma Company Information
  111. 8.19.2 Mayne Pharma Business Overview
  112. 8.19.3 Mayne Pharma Dermatology Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Mayne Pharma Dermatology Drug Product Portfolio
  114. 8.19.5 Mayne Pharma Recent Developments
  115. 8.20 Merck KGaA
  116. 8.20.1 Merck KGaA Company Information
  117. 8.20.2 Merck KGaA Business Overview
  118. 8.20.3 Merck KGaA Dermatology Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Merck KGaA Dermatology Drug Product Portfolio
  120. 8.20.5 Merck KGaA Recent Developments
  121. 8.21 AstraZeneca plc
  122. 8.21.1 AstraZeneca plc Company Information
  123. 8.21.2 AstraZeneca plc Business Overview
  124. 8.21.3 AstraZeneca plc Dermatology Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 AstraZeneca plc Dermatology Drug Product Portfolio
  126. 8.21.5 AstraZeneca plc Recent Developments
  127. 8.22 Roivant Sciences (Dermavant Sciences)
  128. 8.22.1 Roivant Sciences (Dermavant Sciences) Company Information
  129. 8.22.2 Roivant Sciences (Dermavant Sciences) Business Overview
  130. 8.22.3 Roivant Sciences (Dermavant Sciences) Dermatology Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Roivant Sciences (Dermavant Sciences) Dermatology Drug Product Portfolio
  132. 8.22.5 Roivant Sciences (Dermavant Sciences) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst